2022 World Conference on Lung Cancer (ePosters)-EP08.02-167. Diverse Effects of Radiotherapy for Osimertinib Acquired Resistance Non-small Cell Lung Cancer: Gene Matters

EP08.02-167. Diverse Effects of Radiotherapy for Osimertinib Acquired Resistance Non-small Cell Lung Cancer: Gene Matters

Back to course

Pdf Summary

This study aimed to explore the value of radiotherapy in different subclones of osimertinib-acquired resistance non-small cell lung cancer (NSCLC). The IC50 for osimertinib was found to be different in the acquired resistance cells compared to the original cells. Whole-exome sequencing revealed numerous SNPs and INDEL changes in the acquired resistance cells after radiotherapy. When comparing the changes in SNPs between two different cells, 25 SNPs were found to be changed in both. Colony-formation assay identified six subclones, with varying radiosensitivity. The most radioresistant subclone had a SER of 0.69, while the most radiosensitive subclone had a SER of 1.43. These findings suggest that osimertinib resistance in NSCLC has complex mechanisms, and different resistance mechanisms may have different radiosensitivity. Overall, this study highlights the potential importance of radiotherapy in treating osimertinib-acquired resistance NSCLC, but further research is needed to fully understand its role in this context.

Asset Subtitle

Yasi Xu

Meta Tag

Speaker Yasi Xu

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

radiotherapy

osimertinib-acquired resistance

non-small cell lung cancer

IC50

whole-exome sequencing

SNPs

INDEL changes

colony-formation assay

subclones

radiosensitivity